Local recurrence in mismatch repair-proficient colon cancer predicted by an infiltrative tumor border and lack of CD8+ tumor-infiltrating lymphocytes.
OBJECTIVE
The identification of colon cancer patients at high risk of local recurrence is necessary to improve the selection of patients for more tailored treatment protocols. The aim of this study was to develop a predictive model of local recurrence by assessing the independent predictive effect of 7 clinicopathologic features, 24 protein markers of tumor progression, and their multifeature combinations in mismatch repair-proficient colon cancers.


METHODS
Immunohistochemistry for 24 protein markers was done on 269 patients with complete clinicopathologic data. After univariate and multivariable analyses, independent predictors of local recurrence were identified and their multifeature combinations were analyzed. Kaplan-Meier and Cox proportional hazards regression were done for survival analysis.


RESULTS
Local recurrence was observed in 119 patients (55.8%). Independent predictors of tumor recurrence were lymph node involvement (P = 0.006), absence of CD8+ tumor-infiltrating lymphocytes (TIL; P < 0.001), and infiltrative tumor margin (P < 0.001). This independent effect persisted after adjusting for adjuvant therapy. Risk of recurrence was 0.75 and the 5-year survival rate was 8.8% in patients with these three adverse features. Node-negative patients with an infiltrative tumor margin and absence of CD8+ TILs were identified as high risk with a probability of 0.55 for recurrence and a 60% 5-year survival rate. The remaining node-negative cases fared significantly better with risks ranging from 8% to 26% and 5-year survival rates reaching 97.6%.


CONCLUSIONS
An infiltrative tumor margin and absence of CD8+ TILs are highly predictive of local recurrence in node-negative mismatch repair-proficient colon cancer and may help to identify high-risk patients who may benefit from adjuvant chemotherapy.
Zlobec
Inti
I
Institute of Pathology, University Hospital of Basel, Basel, Switzerland. izobec@uhbs.ch
Terracciano
Luigi M
LM
Lugli
Alessandro
A
D018414:CD8-Positive T-Lymphocytes / Q000473:pathology*; D003110:Colonic Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000276:immunology* / Q000473:pathology; D053843:DNA Mismatch Repair; D003661:Decision Support Techniques; D005260:Female; D006801:Humans; D016246:Lymphocytes, Tumor-Infiltrating / Q000473:pathology*; D008297:Male; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis* / Q000235:genetics / Q000276:immunology; D011379:Prognosis; D012372:ROC Curve; D012680:Sensitivity and Specificity; D016019:Survival Analysis